Weekly Recap | MICOT PHARMA-B +56.62%, MT200605 ethics approval in hand

LongbridgeAII'm LongbridgeAI, I can summarize articles.

The Week

MICOT PHARMA-B (2335.HK) rallied 56.62% this week to close at HK$18.81, outperforming the Hang Seng Index by around 51.97 percentage points. Weekly amplitude was 77.18% and turnover surged, with average daily volume of 13.1m shares, about 28 times the 60-session median. Monday opened at 12.05 and hit an intraday high of 20.24 before settling at 16.00. Tuesday and Wednesday pulled back and consolidated, then Thursday climbed again to an intraday high of 21.32 and closed at 18.81, holding above the 16.00 level.

Key Events

The company’s main announcements landed on the evening of 4 November: a voluntary announcement disclosed receipt of the first tranche of RMB 960,000 under the National Major Science and Technology Project, along with ethics approval from the lead institution for the MT200605 Phase III clinical trial. The same day brought a separate announcement on a mandate to buy back up to 10% of H shares. During the week, intraday moves of more than 6% to 12% appeared repeatedly in market flashes, with the 6 November morning feed already referencing the MT200605 Phase III approval. After the close on 6 November came another announcement about delaying an extraordinary general meeting and changing the book closure period, which had less direct bearing on the week’s share-price theme.

Analyst Ratings

Coverage totals one broker, which rates the stock buy; the industry median is two. The consensus rating is strong buy, with a consensus target of HK$38.00, about 102.05% above the latest price. The target range is effectively a single point at HK$38.005, so disagreement is minimal. The stock ranks 39 out of 52 within the biotechnology industry.

The Week Ahead

The company reports fiscal Q3 2026 earnings before market open on Friday, 27 November. On the macro side, Hong Kong unemployment (prior 3.9) lands on Tuesday, 17 November, and the Composite CPI (prior 1.9) on Friday, 20 November. The focus will be whether Q3 results can extend the attention generated by this week’s clinical progress, and how macro data shapes risk appetite across biotech names.

In Short

The core theme this week was the overlap of a clinical pipeline update and unusually volatile trading: MT200605 Phase III received lead-site ethics approval and the first tranche of state funding, while the share price surged on heavy volume. The sole covering broker rates it strong buy with a consensus target about 102% above spot, but coverage is thin and the industry rank sits in the lower half. With the valuation above its historical average, the next test is whether quarterly results and further clinical data can add substance to the move.

This article is generated by LongbridgeAI from market data, for information only and not investment advice.

Source: Weekly Review The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.